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SUMMARY
Background
Helicobacter pylori is one of the most prevalent global pathogens and can
lead to gastrointestinal disease including peptic ulcers, gastric marginal zone
lymphoma and gastric carcinoma.
Aim
To review recent trends in H. pylori antibiotic resistance rates, and to dis-
cuss diagnostics and treatment paradigms.
Methods
A PubMed literature search using the following keywords: Helicobacter
pylori, antibiotic resistance, clarithromycin, levofloxacin, metronidazole,
prevalence, susceptibility testing.
Results
The prevalence of bacterial antibiotic resistance is regionally variable and
appears to be markedly increasing with time in many countries. Concor-
dantly, the antimicrobial eradication rate of H. pylori has been declining
globally. In particular, clarithromycin resistance has been rapidly increasing
in many countries over the past decade, with rates as high as approximately
30% in Japan and Italy, 50% in China and 40% in Turkey; whereas resis-
tance rates are much lower in Sweden and Taiwan, at approximately 15%;
there are limited data in the USA. Other antibiotics show similar trends,
although less pronounced.
Conclusions
Since the choice of empiric therapies should be predicated on accurate
information regarding antibiotic resistance rates, there is a critical need for
determination of current rates at a local scale, and perhaps in individual
patients. Such information would not only guide selection of appropriate
empiric antibiotic therapy but also inform the development of better meth-
ods to identify H. pylori antibiotic resistance at diagnosis. Patient-specific
tailoring of effective antibiotic treatment strategies may lead to reduced
treatment failures and less antibiotic resistance.
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INTRODUCTION
Helicobacter pylori is one of the most prevalent global
pathogens and colonises an estimated 50% of the world’s
population.1, 2 It was first described in gastric biopsies
by Warren and Marshall in Australia in 1983.3–5 H. py-
lori is a Gram-negative bacillus that infects the human
stomach mucosa and produces diseases of the upper gas-
trointestinal tract such as chronic gastritis, peptic ulcer
disease, gastric marginal zone/mucosa-associated lym-
phoid tissue (MALT) lymphoma and gastric carci-
noma.3, 4, 6, 7 More recently, it has been suggested that
H. pylori may be associated with extraintestinal diseases,
including immune thrombocytopenic purpura, refractory
iron deficiency anaemia and vitamin B12 defi-
ciency.1, 8, 9
The precise epidemiology of H. pylori infection still
remains unclear; however, studies have shown that inges-
tion of contaminated food may increase the risk of
H. pylori infection. Person-to-person transmission by
oral-oral, faecal-oral or gastro-oral exposure is suggested
to be the most likely route of transmission.10 Accord-
ingly, improvements in hygiene and living conditions are
important factors in decreasing the prevalence of infec-
tion.11 In addition, mammal and insect reservoirs have
been suggested such as pigtailed monkeys, rhesus mon-
keys, cats, sheep and cockroaches.12 There have also been
association studies with maternal infection and socioeco-
nomic status being an important risk factor for paedi-
atric infection.13–17
Current treatment of H. pylori in the United States is
empiric despite relatively high failure rates in more than
20% of cases.18 In the early 1990s the eradication rate of
H. pylori was greater than 80%.19–21 However, the
antimicrobial eradication rates are decreasing – as low as
60% in some countries – and are inversely correlated
with antibiotic resistance rates reported worldwide.19, 20
Eradication failures are concerning at the present time,
but they are likely to be more critical in the future, given
that global rates of antibiotic resistance are increasing
and therapy for H. pylori infection is increasingly pre-
scribed.21–24 This is reflected in the most recent Maas-
tricht recommendations which state that susceptibility
testing should be performed prior to therapy in regions
with high clarithromycin resistance rates.1 According to
the recent Kyoto Global Consensus Meeting, only regi-
mens shown to result in at least a 90% eradication rate
in a particular region should be used as empiric ther-
apy.25 Therefore, the goal in designing a treatment regi-
men should focus on a strategy which results in a cure
rate approaching 100%.21, 26–28
PREVALENCE OF H. PYLORI INFECTION
Infection with H. pylori occurs worldwide, but there are
substantial geographic differences in the prevalence of
infection both within and between countries.29 Multiple
studies have demonstrated that low socioeconomic status
is associated with increased risk of H. pylori infec-
tion.30, 31 Additionally, an age-related cohort effect has
been observed with prevalence of infection increasing
with age.31–33 Within Europe, H. pylori prevalence rates
range from 11% in Sweden to 60.3% in Spain.29, 34 In
China, H. pylori prevalence has been reported as high as
83.4%.35 Additionally, many countries such as China,
Japan and Bulgaria have experienced an overall increase
in the prevalence of H. pylori infection over the last
20 years (Figure 1).29, 34–53 In Canada, the prevalence of
H. pylori is approximately 30%; however, within the
Aboriginal populations living in Canada, the prevalence
of H. pylori has been reported as high as 95%.54, 55 In
the USA, cross-sectional studies of the participants in
the National Health and Nutrition Examination Survey
(NHANES) III and NHANES 1999–2000 demonstrate an
overall seropositivity rate of approximately 30%.29, 56 In
populations with high infection rates, it is likely that
patients are infected with more than one strain of H. py-
lori.
PREVALENCE OF ANTIBIOTIC RESISTANCE
The prevalence of bacterial resistance varies in different
geographic areas and appears to be increasing with time
in many countries.57, 58 While the overall prevalence of
H. pylori in the USA has been similar in studies from
both 2000 and 2010, the antimicrobial eradication rates
for H. pylori have been decreasing over that interval for
several reasons; the most likely primary reasons for treat-
ment failure were found to be H. pylori resistance to one
or more of the antibiotics and patient compli-
ance.1, 23, 29, 53, 59–61
The European Multicentre Study Group included 2204
patients from 2008 to 2009, spanning 18 European coun-
tries and demonstrated H. pylori resistance rates to clar-
ithromycin, metronidazole and levofloxacin at 17.5%,
34.9% and 14.1% respectively.22 The Japanese National
Surveillance Study looked at 3707 H. pylori isolates from
2002 to 2005. Kobayashi et al. found that clarithromycin
resistance rates increased from 18.9% to 27.7% between
this 3-year interval. Metronidazole resistance remained
fairly consistent, ranging from 3.3% to 5.3%. Amoxicillin
resistance rates were negligible.62 The Surveillance of
H. pylori Antimicrobial Resistance Partnership (SHARP)
program meta-analysis conducted between 1993 and
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1999 demonstrated that the resistance rates to clar-
ithromycin, metronidazole and amoxicillin are 10.1%,
36.9% and 1.4% respectively.57 The prospective multicen-
ter Helicobacter pylori Antimicrobial Resistance Monitor-
ing Program (HARP) study examined the national
incidence rates of H. pylori antimicrobial resistance
between 1998 and 2002; this study demonstrated the
resistance to clarithromycin, metronidazole and amoxi-
cillin as 12.9%, 25.1% and 0.9% respectively.63
There is evidence that bacterial resistance is correlated
with the general consumption of antibiotics in the general
population.22, 64 In a study focused on the Alaskan Native
population, prior use of a macrolide was associated with
increased H. pylori clarithromycin resistance. Overall, 37%
of this Alaskan Native population was infected with clar-
ithromycin-resistant strains of H. pylori and, of these
patients, 92% had previously been treated with a macrolide.
Additionally, McMahon et al. found a dose–response rela-
tionship between clarithromycin resistance and the number
of prior macrolide courses. Within this population, a similar
association was found with infection by metronidazole-resis-
tant H. pylori strains and prior metronidazole use.65–67 Eval-
uating and understanding this relationship between previous
antimicrobial use and H. pylori antimicrobial resistance
would help to increase cure rates.68, 69
Clarithromycin
Numerous studies have been performed to determine the
prevalence of H. pylori resistance to particular antibiotics.
In particular, clarithromycin-resistant H. pylori has been
extensively studied. The prevalence has been increasing in
many countries (Figure 2a).22, 48, 70–85 Studies have shown
that in countries with low rates of H. pylori seropositivity,
the prevalence of antibiotic resistance does not appear to
change considerably over time. For instance, H. pylori
seropositivity rates in Sweden have remained approxi-
mately 20% since 1995.29, 48, 49 The prevalence of clar-
ithromycin-resistant strains of H. pylori has also remained
low (below 5%) over this period of time.48, 74, 79 In con-
trast, countries with higher rates of H. pylori seropositivity
are associated with dramatically increasing rates of clar-
ithromycin resistance. For example, Horiki et al. demon-
strated that the prevalence of clarithromycin resistance
has increased considerably from 1.8% in 1996 to 27.1% in
2008 in the Japanese population.70 Okamura et al.
described an overall resistance rate of 31.1% in patients
studied between 2000 and 2013.71 The prevalence of
H. pylori seropositivity over this time period has increased
from approximately 40% to 55%.29,36,70 Similarly, China
has experienced an increase in clarithromycin resistance
from 14.8% in 2000 to 52.6% in 2014 with an increase in
seropositivity rates from approximately 65% to
83%.35, 37, 38, 72–74 In addition, a marked increase in
prevalence of clarithromycin resistance was seen in Korea
from 11% in 2005 to 60% in 2009.76–78 The variability of
clarithromycin resistance seen in different regions empha-
sises the need to examine resistance rates in each geo-
graphic area to better guide treatment regimens. Within
the USA, the prevalence of clarithromycin resistance has
increased from 6.1% in 1993 to 12.9% in 2002.58, 61, 84 A
recent report studying a population of military veterans
from the USA between 2009 and 2013 demonstrated an
overall 17.8% clarithromycin resistance rate.85 Within the
paediatric population, the rate of clarithromycin resistance
has been reported to be as high as 50%.86 The dramatic
increase in clarithromycin resistance observed in recent
reports from the USA suggests the need for an updated
national survey.
90
80
70
60
In
fe
ct
io
n 
pr
ev
al
en
ce
 (%
)
50
40
30
20
10
0
‘93 ‘94 ‘95 ‘96 ‘97 ‘98 ‘99 ‘00 ‘01 ‘02
Year
‘03 ‘04 ‘05 ‘06 ‘07 ‘08 ‘09 ‘10 ‘11
Japan
China
Taiwan
Korea
Spain
Italy
Sweden
Bulgaria
Turkey
USA
Figure 1 | Global prevalence of
H. pylori infection by country
and year.29, 34–53
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Metronidazole
Overall, metronidazole resistance rates have been increas-
ing in many countries (Figure 2b).62, 65, 71–77, 79, 81–
84, 87–106 The prevalence of H. pylori resistance to
metronidazole ranges from 20% to 40% in Europe and
the USA, with one exception in Northern Italy
(14.9%).100 The overall resistance rate to metronidazole
was 33.1% in Europe with no substantial difference
between Northern and Southern Europe; however, a
noticeably lower prevalence was found in Central and
Eastern Europe.100, 107–111 A higher prevalence has been
reported in developing countries (50%–80%), for
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Figure 2 | (a) Global
prevalence of clarithromycin
antibiotic resistance by
country and year.22, 48, 70–85
(b) Global prevalence of
metronidazole antibiotic
resistance by country and
year.62, 65, 71–77, 79, 81–84, 87–106
(c) Global prevalence of
levofloxacin antibiotic
resistance by country and
year.22, 67, 72–74, 77, 81–
83, 85, 87, 88, 90, 95, 96, 106, 117–
121 Hashed band indicates
threshold for altering
therapeutic intervention.
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example Mexico (76.3%).110 The prevalence of metron-
idazole resistance tends to be lower in Japan (9–12%).94
The prevalence in Canada was reported from 18% to
22%.112 Metronidazole resistance rates in a US popula-
tion was recently reported as 21.5%.85 One possible
explanation includes different rates of prior metronida-
zole use in various countries. As seen in Alaskan
Native populations, women have higher rates of metron-
idazole resistance than men, and prior use of metronida-
zole was associated with increased metronidazole
resistance.65 The finding of higher rates in Alaskan
Native women may be related to antibiotic treatment of
gynecological infections, although this was not specifi-
cally studied.65–67
Other antibiotics
It has been reported that resistance to tetracycline is as
low as 0.7% in Spain, 0.5% in the UK and 0.5% in the
Hong Kong, or even absent in most countries.22, 113–115
The prevalence of resistance to fluoroquinolones has
been determined in only a limited number of studies.1 In
China and Italy, levofloxacin resistance rates have been
reported as 34.5% and 22.1% respectively.73, 81 Surpris-
ingly, a recent study from the USA demonstrated a levo-
floxacin resistance rate of 31.9%; this resistance rate
needs to be confirmed with additional studies.85 Portu-
gal, has reported a high resistance rate of 20.9% in
strains isolated from 110 adult patients.116 Although this
resistance to this antibiotic has not been studied as
extensively as other antimicrobials, there is a trend of
increasing levofloxacin-resistant H. pylori (Fig-
ure 2c).22, 67, 72–74, 77, 81–83, 85, 87, 88, 90, 95, 96, 106, 117–121
In the Netherlands, a rate of 4.7% resistance was
reported with trovafloxacin, a drug not yet introduced to
the Dutch market; this finding suggests cross resistance
between the different molecules of this antibiotic
group.122 In France, a rate of 3.3% was reported; in five
Eastern European countries, the rate was similar
(3.9%).123, 124 Sitafloxacin appears not to be affected by
prior fluoroquinolones use and has also been shown to
achieve high H. pylori eradication rates.125, 126
Resistance to amoxicillin has been shown to be negli-
gible (0 to <2%) in European countries, such as Ger-
many and the Netherlands.122, 127 In Alaskan Native
populations, 6% of patients were infected with amoxi-
cillin-resistant strains of H. pylori.65 In Asia and South
America, amoxicillin resistance rates have been reported
to be up to 38%.128, 129 However, it has been suggested
that H. pylori resistance to amoxicillin does not reduce
treatment efficacy.95
DIAGNOSIS OF H. PYLORI INFECTION
H. pylori testing has become more common over the last
decade in patients with epigastric pain and dyspepsia.130
H. pylori is considered a group I carcinogen by the
International Agency for Research on Cancer, eradication
of which should reduce the incidence of gastric carci-
noma and MALT/marginal zone lymphoma.4, 6, 131, 132
Investigations to assess for H. pylori infection are
broadly divided into non-invasive and invasive meth-
ods.133–135
Non-invasive methods for H. pylori detection with
subsequent treatment is recommended for patients
younger than 55 years of age presenting with new-onset
dyspepsia without alarm symptoms.134, 135 These tests
include peripheral blood serology, urea breath test and
stool antigen test. Serological testing detects
immunoglobulin G antibodies to H. pylori infection;
however, seroconversion for H. pylori is rare and sero-
logic tests are not recommended by current guide-
lines.1, 136, 137 This test is not suitable for monitoring
post-eradication because successful treatment does not
alter IgG levels immediately.138 Additionally, serologic
tests may perform differently in different ethnic groups.
Serological testing for immunoglobulin M antibodies
directed against H. pylori can detect active infection,
however, IgM levels are only elevated shortly after infec-
tion.139 Urea breath testing is currently the gold standard
for determining H. pylori status. This test uses either
nonradioactive 13C or radioactive 14C to detect urease
activity produced by H. pylori.140 One of the advantages
of this test is its ability to monitor eradication after treat-
ment. Stool antigen testing detects H. pylori antigen in
the stool via monoclonal and polyclonal anti-H. pylori
antibodies.141 Like the urea breath test, stool antigen
testing is capable of monitoring patients in the post-
treatment period.142 This test is a suitable substitute
detection modality in areas where the urea breath test is
not available.133, 143
Upper endoscopy (an invasive procedure) is recom-
mended in the evaluation of all patients presenting with
new-onset dyspepsia with alarm symptoms, including
unintended weight loss, gastrointestinal bleeding, unex-
plained iron-deficiency anaemia and progressive dyspha-
gia.133, 134 Patients with new-onset dyspepsia in the
absence of alarm symptoms are recommended to
undergo upper endoscopy if they are 55 years of age or
greater.133, 134 However, this age criterion is controversial
and may vary by population.135 Determination of an
appropriate age cut-off should take into consideration
the presence of persistent symptoms and the local preva-
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lence of gastric cancer.1, 134 If biopsy samples can be
easily obtained, the rapid urease test is an option. In this
test, two biopsy specimens from the gastric antrum and
body are tested to detect the presence of urease from a
H. pylori infection.144 Although this test is cheaper than
histology, the practice of utilising this test without a
specimen also being sent for histopathologic evaluation
is not recommended due to the diagnostic yield of
histopathology in detecting severity of inflammation and
related pathology, including lymphoma or carcinoma.25
Several ancillary staining methods can be used in con-
junction with routine histological evaluation by hema-
toxylin and eosin stained tissue sections.145 These
include special stains (e.g. modified Giemsa or Warthin–
Starry) and H. pylori immunohistochemical stains.
ANTIBIOTIC THERAPEUTIC REGIMENS
Multiple therapeutic regimens have been developed in
order to treat H. pylori infection (Figure 3).133 If eradica-
tion is not achieved, salvage treatment regimens have
been proposed.
First line therapy (Table 1)
Triple therapy. The effectiveness of antibiotics is related
to many biologic and non-biologic factors including
antimicrobial strength, cost, side effects, duration, tolera-
bility of drugs, local antibiotic use, and bacterial resis-
tance.146, 147 The current standard regimen for H. pylori
treatment in areas where clarithromycin resistance is
below 15% is PPI-based triple therapy which involves
the use of a PPI, clarithromycin and amoxi-
cillin.133, 146, 147 This regimen has been used widely for
more than a decade, however, its efficacy has decreased
globally.12 In cases of penicillin allergy, metronidazole
can substitute for amoxicillin with equivalent effective-
ness to amoxicillin.146 Increased antibiotic resistance,
especially to clarithromycin, is thought to be the main
cause of eradication failure for standard PPI-containing
triple therapy. Additional factors which may impact cure
rates include, but are not limited to, patient compliance,
body weight, type of H. pylori strains, high bacterial
load, gastric acidity and atrophic gastritis.12, 148 As a
result, some authors have suggested avoiding clar-
ithromycin in first-line empiric therapies for areas with
high rates of resistance.59, 149 Per the Maastricht guideli-
nes, sensitivity testing is recommended prior to treat-
ment when H. pylori antibiotic resistance rates exceed
20% in the population of interest.1 In addition, a review
of patients’ prior antibiotic use is important to increase
cure rates as prior exposure to macrolides increase
H. pylori resistance rates to clarithromycin65–67
Nevertheless, 7 days of triple therapy is recommended
in areas where the rate of clarithromycin resistance is
less than 15% based on European guidelines; 14 days of
triple therapy is suggested for areas with clarithromycin
resistance >20%.1, 150 A randomised trial conducted by
Paoluzi et al. compared H. pylori eradication rate
between patients treated with 7 days vs. 14 days of stan-
dard therapy containing amoxicillin, clarithromycin and
omeprazole.151 Although antibiotic resistance rates were
not determined in this study population, the overall
results suggested that 14 days of standard therapy
resulted in increased eradication (77% vs. 66%).151
Bismuth-containing quadruple therapy. Bismuth-con-
taining quadruple therapy consists of a PPI, bismuth
and two antibiotics, such as tetracycline, clarithromycin
and metronidazole.1, 133, 152 The regimen has been pro-
ven effective as the first line of treatment in areas of
high clarithromycin or metronidazole resistance and for
patients with recent or repeated exposure to these
antibiotics.1 The main advantage of this regimen is that
it can overcome clarithromycin or metronidazole resis-
tance, especially when therapy contains both metronida-
zole and clarithromycin, concomitantly.152 A meta-
analysis performed by Fisch and Evans has shown bet-
ter outcomes for bismuth-containing quadruple therapy
as compared to the standard triple therapy in areas
with increased clarithromycin or metronidazole resis-
tance.153
Doxycycline or amoxicillin could be substitutes in
countries where tetracycline and bismuth salts are not
available, although the efficacy data are conflicting.153–158
Limited compliance has been reported due to the
increased number of drugs and frequent dosing.159
Quadruple therapy using combination capsules has
shown promising eradication rates.159
Sequential therapy. Sequential therapy was first intro-
duced by Zullo et al. and consists of a 10-day therapy
comprising 5 days of PPI plus amoxicillin followed by
5 days of triple treatment of a PPI, clarithromycin and
metronidazole.1, 26, 133 Levofloxacin can be used in
patients with penicillin allergy or in areas of high clar-
ithromycin resistance.160 Although this regimen includes
clarithromycin, it is considered an alternative to standard
triple therapy in high clarithromycin-resistant areas.1, 152
This therapeutic regimen employs the use of amoxicillin
prior to clarithromycin in order to overcome
Aliment Pharmacol Ther 2016; 43: 514–533 519
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clarithromycin resistance. Amoxicillin disrupts H. pylori
cell walls and prevents activation of efflux channels, one
of the mechanisms of clarithromycin resistance.160, 161
The drawback of this therapy is its complex regimen
which results in decreased patient compliance.59, 162 If
the patient fails treatment, there is potential to develop
multidrug resistance. Additionally, sequential therapy
utilises the main antibiotics effective against H. pylori,
limiting salvage therapy options.
Concomitant therapy. Concomitant therapy consists of a
PPI, clarithromycin, amoxicillin and metronidazole for at
least 10 days. This regimen has shown superiority over
standard triple therapy, especially in cases of
Positive for H. pylori
Determination of antimicrobial
resistance*
+ + +clarithromycin metronidazole levofloxacin Unknown or low/
clarithromycin resistance
–
resistanceresistance and/or recent
metronidazole exposure
Quadruple therapy
(Table 1)
Sitafloxacin based
therapy (Table 2)
Eradication confirmation:
Testing to be performed 4 weeks
or more after completion of therapy
Salvage therapy
(Table 2)
Positive
Negative
Negative with
persistent
symptoms
Evaluate for other
causes of dyspepsiaStop
Triple therapy 
(Table 1)
resistance and/or recent
macrolide exposure
Figure 3 | Recommended algorithm for the management of H. pylori.134
*In patients who have failed 2 or more courses of therapy, culture and sensitivity testing may be considered.
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clarithromycin resistance. A better result with concomi-
tant treatment was observed vs. standard triple therapy
in recent randomised clinical trials.163, 164 A meta-analy-
sis of nine studies (conducted in Japan, UK, Germany,
Spain and Italy) showed >90% per protocol analysis (PP)
and >80% intention-to-treat (ITT) eradication rates for
concomitant therapy, which was an improvement over
the standard triple therapy.162
Additionally, a recent study conducted in Taiwan eval-
uated concomitant and sequential therapy regimens
using a PPI, levofloxacin, amoxicillin and metronidazole.
The population studied was found to have the following
resistance rates: levofloxacin – 10.2%, amoxicillin – 0.6%,
clarithromycin – 6.6% and metronidazole – 33.5%. ITT
analysis showed comparable eradication rates for levo-
floxacin-based concomitant (92.2%) and sequential
(93.3%) therapies.165
The advantages of concomitant therapy is the efficacy
against dual antibiotic-resistant strains, and the higher
compliance rates compared to the sequential ther-
apy.79, 162, 164, 166 However, it should be noted that the
efficacy of concomitant therapy, as with many treatment
regimens, depends on the prevalence of H. pylori antimi-
crobial resistance, which varies by geography.
Hybrid therapy (sequential-concomitant therapy). Hsu
et al. proposed a hybrid therapy which is a combination
of sequential therapy and concomitant therapy.167 The
hybrid regimens consist of dual therapy with a PPI and
amoxicillin for 7 days, with addition of a concomitant
quadruple therapy with a PPI, amoxicillin, clar-
ithromycin and metronidazole for another 7 days. The
eradication rate was excellent with 99% in PP and 97%
in the ITT analysis, even in dual clarithromycin and
Table 1 | Current initial therapy regimens (Disclaimer: Local resistance rates can markedly impact the choice of
therapy)
Recommendations & comments Regimen
Duration of
therapy
Triple therapy133 Consider in areas of low
clarithromycin resistance or
patients with no prior recent
macrolide exposure
• Standard PPI dose b.d. (esomeprazole
is q.d.)
• Clarithromycin 500 mg b.d.
• Amoxicillin 1000 mg b.d.*
10–14 days
Quadruple therapy133 Consider in areas of high
clarithromycin resistance
or patients with recent or
repeated macrolide exposure
• Standard PPI dose b.d. (esomeprazole
is q.d.)
• Bismuth 525 mg q.d.s.
• Tetracycline 500 mg q.d.s.
• Metronidazole 250 mg q.d.s.
10–14 days
Alternative regimens:
Sequential therapy133 Needs validation in USA • First 5 days: Standard PPI dose b.d. +
Amoxicillin 1000 mg b.d.
• Next 5 days: Standard PPI dose b.d. +
Clarithromycin 500 mg b.d. +
Metronidazole 500 mg b.d.
5 days
5 days
Concomitant therapy163 Needs validation in USA • Standard PPI dose b.d.
• Metronidazole 500 mg b.d.
• Clarithromycin 500 mg b.d.
• Amoxicillin 1000 mg b.d.
10 days
Hybrid therapy167–169 Needs validation in USA • First 7 days: Standard PPI dose b.d. +
Amoxicillin 1000 mg b.d.
• Next 7 days: Standard PPI dose
b.d. + Amoxicillin 1000 mg b.d. +
Clarithromycin 500 mg b.d. +
Metronidazole 500 mg b.d.
7 days
7 days
PPI, proton pump inhibitor; b.d., twice daily; q.d., daily; q.d.s., four times daily.
* Metronidazole 500 mg b.d. can be substituted for patients with a penicillin allergy.
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metronidazole resistance strains.168 A tendency towards
better results seems to be the result of extended use of
amoxicillin for 14 days, compared to sequential or con-
comitant therapy. One randomised clinical trial indicated
that the hybrid therapy had equivalent eradication rates
to 14-day concomitant therapy.169 However, further vali-
dation of these results is needed in order to confirm the
effectiveness of hybrid therapy.169
Salvage therapy (Table 2)
Quinolone-based therapy. The use of levofloxacin has
been proposed as an antibiotic in salvage therapeutic
regimens. After failure to eradicate H. pylori using
standard triple therapy which includes the use of
amoxicillin and clarithromycin, levofloxacin-based triple
therapy is the most validated regimen used as a
second line alternative therapy.170 This quinolone-based
therapy consists of a PPI, levofloxacin and amoxi-
cillin for 10 days. Multiple studies conducted predomi-
nantly in Europe and Taiwan reported variable rates
of eradication (65–96%), perhaps reflecting varying
levels of levofloxacin resistance in the studied popula-
tions.170
Another quinolone regimen consists of levofloxacin,
omeprazole, nitazoxanide and doxycycline (LOAD) for 7
or 10 days. A study consisting of 653 patients conducted
by Basu et al. found that the LOAD regimen led to a
higher rate of eradication when compared to the stan-
dard triple therapy, regardless of the duration of LOAD
therapy (approximately 90% vs. 73%).171 Additionally,
the study demonstrated that patients following the
Table 2 | Current salvage therapy regimens (Disclaimer: Local resistance rates can markedly impact the choice of
therapy)
Recommendations & Comments Regimen
Duration
of therapy
Quadruple therapy133 Consider in patients who were
not initially treated with triple therapy
• Standard PPI dose b.d.
(esomeprazole is QD)
• Bismuth 525 mg q.d.s.
• Tetracycline 500 mg q.d.s.
• Metronidazole 250 mg q.d.s.
7 days
Levofloxacin triple
therapy133,170
Needs validation in USA • Standard PPI dose b.d.
(esomeprazole is q.d.)
• Levofloxacin 500 mg q.d.
• Amoxicillin 500 mg q.d.
10 days
LOAD171 Needs further evaluation • Levofloxacin 250 mg q.a.m.
• Omeprazole 40 mg q.a.m.
• Nitazoxanide 500 mg b.d.
• Doxycycline 100 mg q.p.m.
7–10 days
Rifabutin-based
therapy174
Adverse effect includes myelotoxicity • Standard PPI dose b.d.
• Rifabutin 150 mg b.d.
• Amoxicillin 1000 mg b.d.
10–12 days
Furazolidone quadruple
therapy175
Needs validation in USA • Lansoprazole 30 mg b.d.
• Tripotassiumdicitratobis-
muthate 240 mg b.d.
• Furazolidone 200 mg b.d.
• Tetracycline 1000 mg b.d.
7 days
High-dose dual
therapy55, 177
Needs validation in USA • Amoxicillin 750 mg t.d.s.
• Lansoprazole 30 mg t.d.s.
14 days
Sitafloxacin therapy177 Needs validation • Sitafloxacin 100 mg b.d.
• Metronidazole 250 mg b.d.
• Rabeprazole 10 mg b.d.
7 days
PPI, proton pump inhibitor; b.d., twice daily; q.d., daily; q.d.s., four times daily; q.a.m., each morning; q.p.m., each night; t.d.s., three
times daily.
522 Aliment Pharmacol Ther 2016; 43: 514–533
ª 2015 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
I. Thung et al.
LOAD regimen had decreased rates of recurrence at 1-
year follow-up.171
Levofloxacin-based therapies have also been consid-
ered in empiric third-line therapeutic regimens after
patients have failed to achieve H. pylori eradication with
the use of standard first- and second-line therapies. One
study proposes the use of levofloxacin in a third-line
quadruple therapy in combination with rabeprazole, bis-
muth subcitrate and amoxicillin. Despite the presence of
multi-antibiotic-resistant H. pylori, a 10-day course of
treatment led to an overall 84% eradication rate. It
should be noted that patients who were found to be
amoxicillin or levofloxacin-resistant demonstrated lower
rates of eradication.172
Selection of quinolone therapy should be based on the
results of antibiotic susceptibility tests or geographic
resistance patterns, as quinolone-resistant strains have
increased in concert with the use of quinolones for infec-
tions of the respiratory and urogenital tracts. Therefore,
this regimen is not generally recommended as first-line
treatment.173 Presently this regimen is used as a second-
line treatment in populations where clarithromycin resis-
tance rates are greater than 15%–20% and quinolone
resistance rates are less than 10%. It has also been
demonstrated that levofloxacin-based triple regimen
could be used as an empiric salvage treatment after the
failures of first and second-line therapy in low quinolone
resistance areas.1
Rifabutin-based therapy. Based on in vitro studies, rifa-
butin-based therapy comprising amoxicillin, a PPI, and
rifabutin has shown encouraging effects as a salvage
treatment for H. pylori eradication. However, duration of
treatment with this anti-tuberculous agent remains
unclear (7-day vs. 10-day vs. 14-day). In addition, rare
myelotoxicity is an important complication that needs to
be overcome prior to rifabutin’s widespread applica-
tion.174 Because of the potential for mycobacterial resis-
tance this regimen should be reserved only for rescue
treatment. Rifabutin-based triple therapy could be used
as an empiric third line salvage treatment and is listed in
guidelines for areas in which bismuth and tetracycline
are not available, although shortages in the USA have
been temporary.1, 174
Furazolidone-based therapy. Furazolidone-based therapy
is a 1-week therapy with lansoprazole, tripotassiumdici-
tratobismuthate, tetracycline and furazolidone that has
been used as salvage treatment, after second-line treat-
ment failure. This salvage therapy has achieved 90%
eradication rate in one analysis.175 However, the problem
with this regimen is the high incidence of side effects
and cross resistance with metronidazole.175
High-dose dual therapy. High-dose dual therapy has
been evaluated in high clarithromycin resistance areas.
This regimen consists of a PPI and amoxicillin three
times a day for 14 days.176, 177 In one study patients
were randomly given one of two regimens: (i) 1000 mg
amoxicillin with 500 mg clarithromycin and 30 mg lan-
soprazole b.d. for 2 weeks (triple therapy group), (ii)
750 mg amoxicillin with 30 mg lansoprazole t.d.s. for
2 weeks.176 The eradication rate was 82.8% for standard
triple therapy vs. 78.4% for high dose dual therapy,
although the difference was not statistically significant.176
While these results are promising, additional studies to
validate and optimise the treatment regimen (including
differences between PPI used) are needed before it can
be established as a main therapeutic regimen.178
ANTIBIOTIC RESISTANCE MECHANISMS
Amoxicillin
Amoxicillin is a moderate-spectrum, bactericidal, beta-
lactam antibiotic in the penicillin family. The main
mechanisms leading to amoxicillin resistance of H. pylori
are alterations in penicillin-binding proteins, decreased
membrane permeability of antibiotics into the bacterial
cell or combinations of these resistance strategies.
Expression of active efflux pumps that excrete drugs and
point mutations in the pbp1A gene may contribute to
the mechanisms of resistance to beta-lactams. Other
mutations such as pbp2, hefC, hopC and hofH have been
identified among H. Pylori-resistant strains.179
Clarithromycin
Clarithromycin is a bacteriostatic antibiotic that inhibits
bacterial protein synthesis by reversibly binding to the
50S ribosomal subunits. The 50S ribosomal subunit is
itself composed of 23S ribosomal RNA, 5S ribosomal
RNA, and RNA binding proteins. The peptidyl trans-
ferase loop of the V domain of 23S ribosomal RNA
molecule is the target site of clarithromycin. Resistance
to clarithromycin is generally caused by point mutations
in the 23S rRNA gene, the most frequent is A2143G
(69.8%), followed by A2142G (11.7%) and A2142C
(2.6%).79 These mutations prevent the macrolide from
binding. Moreover, other mutations such as A2115G,
G2141A, C2147G, T2190C, C2195T, A2223G and
C2694A have been implicated in the development of
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clarithromycin resistance, although their precise role in
the mechanism of resistance remains unclear.180
Metronidazole
Metronidazole, a bactericidal antibiotic, is a synthetic
nitroimidazole. This prodrug is activated by nitroreduc-
tases within the cytosol of the microorganism, produc-
ing a toxic metabolite. In metronidazole-resistant
strains, null mutations in the rdxA gene have been
identified. The genecodes for an oxygen-insensitive
NADPH nitroreductase (RdxA), whose expression is
necessary for intracellular activation of the drug, and
the mutations causes inactivation of these nitroreduc-
tases. Nonetheless, a number of resistant strains have
been reported, such as frxA (coding for NADPH flavi-
noxidoreductase), and fdxB (coding for ferredoxin-like
enzyme), which can also confer resistance to metron-
idazole.181–183
Tetracycline
Tetracycline is a bactericidal antibiotic which inhibits
protein synthesis by binding to the 30S subunit of ribo-
somes; this blocks the binding of aminoacyl-tRNA,
resulting in stalled synthesis of nascent peptide chains.
Antibiotic resistance to tetracycline is due to an
enhanced energy-dependent efflux of tetracycline-cation
complexes across the cell membrane by membrane-asso-
ciated efflux proteins which decreases the intracellular
concentration of tetracycline.184 Conversely, sensitivity to
tetracycline is increased by deletions in these efflux
genes.184
Another mechanism of tetracycline resistance is medi-
ated through ribosomal protection proteins. These pro-
tection proteins increase tetracycline resistance either by
decreasing the affinity of ribosomes for tetracycline or by
releasing the bound antibiotic from the ribosome. Addi-
tionally, two other mechanisms have been reported
including enzymatic inactivation of tetracycline and
point mutations in the 16S rRNA genes that affect the
binding site of tetracycline.184
Levofloxacin
Point mutations of gyrA, which codes for DNA gyrase,
have been identified in the quinolone-resistant determi-
nation region with the major mutations being found at
position in the codons coding for amino acid 87, 88, 91
or 97, conferring resistance of levofloxacin and other
quinolones.185, 186 However, studies have shown that
sitafloxacin may overcome the resistance conferred by
these point mutations.187, 188
Rifabutin
Resistance to rifabutin is generally caused by point muta-
tion in codons 524–545 or codon 585 of the rpoB
gene.189, 190 Moreover, cross resistance between rifabutin
and rifampin has been reported.191
TECHNIQUES FOR DETECTING H. PYLORI
ANTIBIOTIC RESISTANCE
(TABLE 3)184–186, 189, 192, 193
Endoscopic-guided antibiotic susceptibility testing has
been suggested not only for treatment after failure of
second-line therapies but also for determining antibiotic
susceptibility prior to the administration of a first-line
clarithromycin-containing therapy, especially in areas of
high clarithromycin resistance.194–196 Currently, several
techniques exist for evaluating antibiotic resistance in
H. pylori, but differ in the timing and character of the
requisite analytic specimen.
Culture-based techniques
In vitro susceptibility testing of H. pylori using agar dilu-
tion method are practical for testing large numbers of
strains; it is not suitable for the testing of small numbers
of strains on an ongoing basis.194–197 The Epsilometer
test (E-test) method involves the use of test strips
applied to an inoculated agar plate in order to determine
the antibiotic’s minimum inhibitory concentration.198
One study found the E-test produced reproducible
results in determining the sensitivity of H. pylori isolates
to ampicillin, clarithromycin and metronidazole.198, 199
From an international perspective, E-test appears to be a
suitable method for determining H. pylori antibiotic sen-
sitivity.199–201 However, the availability of the E-test
strips for one of the key antibiotics of interest, clar-
ithromycin, is currently not globally available for clinical
use.
One of the main drawbacks of both the agar dilution
and E-test is that they only test a single H. pylori strain.
In areas of high H. pylori prevalence and increased likeli-
hood of patients being infected with multiple H. pylori
strains, these two testing modalities may fail to provide
complete antimicrobial resistance data.
Molecular techniques
The gold standard methods of antibiotic resistance are
based on phenotypic methods performed by the agar
dilution method.194, 202 These methods, however, can
take up to 2 weeks to be completed. Detection of point
mutations using molecular methods was developed in
part to shorten the turn-around time. In addition,
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molecular techniques can often use either fresh or for-
malin-fixed samples.
Real-time PCR has been used to successfully deter-
mine H. pylori susceptibility to clarithromycin.203, 204
Additionally, PCR using formalin-fixed paraffin-
embedded samples has been shown to reliably detect the
H. pylori 23S rRNA mutations associated with clar-
ithromycin resistance.86 Another advantage of PCR is
the potential to gather complete antimicrobial resistance
data in patients infected with multiple strains of H. py-
lori. Although the use of PCR-based methods provides
rapid detection of micro-organisms, these techniques can
be affected by DNA contamination or degradation since
the high sensitivity of these methods often result in the
detection of dead or nonculturable microorganisms.205
Fluorescence in situ hybridisation (FISH) is a time-
saving, accurate and cost-effective method for the detec-
tion of antibiotic resistance in cultured H. pylori colo-
nies. This method can be used directly on biopsy
specimens procured for histopathological and microbio-
logical examination, allowing for rapid detection of
H. pylori resistance without requiring DNA prepara-
tion.201, 206 The results can theoretically be available
within 3 hours after an endoscopy by utilising frozen tis-
sue sections.205 The limitations of this method include
the degradation of the probe by proteases and nucleases
present in the sample and poor accessibility of the
microbial cell wall for the probes.
Recently, peptide nucleic acid (PNA) probes using
FISH have been used for the detection of several bacteria
in lieu of the typical DNA molecular probes.175, 207 PNA
molecules are DNA mimics with high affinity for DNA
or RNA complementary sequences.208, 209 PNA probes
are normally relatively small (13–18 nucleotides),
increasing their ability to penetrate the bacterial cell wall.
Moreover, the PNA molecules are more resistant to
nucleases and proteases than DNA molecules.
CONCLUSIONS AND FUTURE DIRECTIONS
Helicobacter pylori infection remains a very common
worldwide condition with strong geographic variations
and the prevalence of antibiotic resistance appears to be
rapidly increasing. This is particularly evident in coun-
tries such as Japan, Korea and China, in which antibiotic
resistant strains of H. pylori have been studied most
extensively (Figure 2). Indeed, many countries have
crossed the 15–20% threshold for antibiotic resistance
over the past 20 years (Figure 2). During this period of
increasing antibiotic resistance, the eradication rate of
empiric therapy for H. pylori has dropped below the
Table 3 | Current techniques for detecting H. pylori antibiotic resistance
Name of the
method Basis for method Sensitivity Specificity Advantages of the method
Disadvantages of the
method
Agar Dilution
Method
Based on phenotypic
methods failure of
second-line therapies
– – Adaptable for the testing of
large numbers of strains
Technically
demanding
Time consuming
Epsilometer Test
(E- test)
Method184
Based on phenotypic
methods
45% 98% Adaptable for testing of small
numbers of strains
Less technically demanding
Time consuming
PCR-based
methods185
Based on detection of
point mutations
98% 92% High-sensitivity
Rapid detection of
microorganisms
Affected by DNA
contamination
FISH-Based
Method186
Fluorescent-labelled
DNA probes to identify
DNA sequences on
chromosomes
97% 94% Time-saving
Accurate
Cost-effective
Degradation of the
probe by proteases
Inability to penetrate
the bacterial cell
wall (fresh tissue)
PNA-FISH-Based
Method189
Fluorescently-labelled
PNA probes to identify
DNA sequences on
chromosomes
80% 93.8% Ability to penetrate the
bacterial cell wall
Resistant to nucleases
and proteases
Not widely available
for standardisation
Line Probe
Test192,193
DNA-based test to
identify multiple
variants simultaneously.
Commercialised as kits
for laboratories.
100% 86.2% Fast, standardised test that
examines both clarithromycin
and fluoroquinolones
resistance
Not available in the
USA
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80–90% target, and failure rates range from 29% in the
USA to 40% in Western Europe and Japan.25, 210, 211
Treatment failure is multifactorial and requires further
study, but is likely due to poor compliance and antibiotic
resistance. In addition, reinfection rates are unclear and
may influence measured treatment failures.212, 213 Vari-
able antibiotic susceptibility of different H. pylori strains
found within the antrum of the stomach vs. the corpus
may also be contributing to treatment failure.25, 127 The
cagA status of bacterial strains is also a risk factor for
treatment failure as H. pylori eradication was more suc-
cessful in patients harbouring cagA+ strains compared
with those infected with cagA strains.212, 214 This find-
ing may explain why cure rates are higher in patients
with peptic ulcer disease than those with non-ulcer dis-
ease.212, 215 Additionally, patients who fail first-line ther-
apy have been shown to develop secondary resistance to
the recommended antibiotics, further promoting the
selection of antibiotic-resistant H. pylori strains.216
Theoretically, the widespread general usage of antibi-
otics by the public may be further contributing to the
development and increased prevalence of antibiotic-resis-
tant strains of H. pylori. Globally, antibiotic consumption
increased by 36% between 2000 and 2010, mainly in
developing countries. Perhaps even more importantly,
one of the largest absolute increases in consumption was
observed for broad-spectrum antibiotics. This overall
increase in antibiotic consumption also includes a global
increase in macrolide consumption by approximately
20% over this time period.217 As antibiotic resistance has
been correlated with antibiotic usage, the continual
increase in usage of broad-spectrum antibiotics in recent
years suggests that rates of H. pylori antibiotic resistance
might be increasing in parallel.59, 150 Importantly,
the prior usage of macrolides and, specifically,
clarithromycin has been shown to directly impact
the development of antibiotic-resistant strains of
H. pylori.22, 64, 65
Because of the clinical importance of decreased eradica-
tion rates, regional variation in antibiotic resistance rates
and the marked increase over time of antibiotic resistance
rates in the past 15 years, there is a critical need to deter-
mine the current rates of local antibiotic resistance. Such a
determination would not only facilitate the selection of
appropriate antibiotic treatment regimens but also serve
as a potential basis for transitioning to individualised
analysis of antibiotic resistance prior to definitive treat-
ment. Therefore, a paradigm shift in therapy towards
patient-specific tailoring of effective antibiotic treatment
strategies may lead to reduced treatment failures and stem
the tide of increasing H. pylori antibiotic resistance in var-
ious populations throughout the world.
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